PPIs Are Not Just for Heartburn—They Treat Multiple Acid-Related Conditions
Proton pump inhibitors (PPIs) are definitively indicated for peptic ulcers, GERD (including heartburn), prevention of NSAID/aspirin-induced ulcers in high-risk patients, H. pylori eradication therapy, and several other acid-related conditions—they are far more than just heartburn medications. 1
Established Indications for PPI Use
PPIs work by inhibiting the parietal cell proton pump, providing potent suppression of gastric acid secretion. Their approved and evidence-based uses include:
Primary Treatment Indications
- Peptic ulcer disease (both gastric and duodenal ulcers) 1, 2
- Gastroesophageal reflux disease (GERD), including:
- Symptomatic GERD (heartburn and regurgitation)
- Erosive esophagitis (particularly Los Angeles grade C/D)
- Maintenance therapy to prevent GERD complications 1
- H. pylori eradication (in combination with antibiotics) 3, 2
- Barrett's esophagus (to reduce esophageal adenocarcinoma risk) 1
- Eosinophilic esophagitis (first-line pharmacologic therapy) 1
- Zollinger-Ellison syndrome and other hypersecretory conditions 3, 2
Gastroprotection Indications
PPIs are superior to H2-receptor antagonists and misoprostol for preventing NSAID-related ulcers and improving overall symptom control and quality of life. 4 Specific gastroprotection uses include:
- Prevention of NSAID-induced gastroduodenal ulcers in high-risk patients 4, 2
- Prevention of aspirin-related ulcers in patients with history of ulcer complications—even after H. pylori eradication, PPI therapy provides additional protection 4
- Secondary prevention after ulcer bleeding in patients requiring continued antiplatelet therapy 4
- Stress ulcer prophylaxis in ICU patients with specific risk factors 1
Additional Evidence-Based Uses
- Idiopathic pulmonary fibrosis (to reduce disease progression) 1
- Functional dyspepsia (short-term trial may be appropriate) 1, 2
- Prevention of rebleeding after endoscopic treatment of peptic ulcer bleeding 5
- Refractory steatorrhea in chronic pancreatic insufficiency with enzyme replacement 1
Key Clinical Points
When PPIs Are Superior
PPIs have been proven superior to ranitidine and misoprostol in preventing NSAID ulcer recurrence, largely due to their ability to reduce ulcers and improve NSAID-associated dyspepsia, thereby improving quality of life. 4 In patients taking low-dose aspirin with history of ulcer bleeding, lansoprazole 30 mg daily significantly reduced recurrence of ulcer complications compared to placebo, even after H. pylori eradication. 4
Standard Dosing Is Usually Sufficient
The literature does not support the need for greater than standard once-daily dosing for ulcer disease indications, despite higher doses providing greater acid suppression. 4 Standard doses are typically adequate for both treatment and prevention.
Common Pitfall: Overuse Without Indication
PPIs are among the most widely prescribed medications worldwide, but they are frequently prescribed without appropriate indication or continued longer than necessary. 6, 5, 2 Approximately 10% of some populations are current PPI users, often without clear clinical justification. 6 This exposes patients to potential risks without benefit.
Conditions Where PPIs Should NOT Be Discontinued
Patients with the following should generally not have PPIs de-prescribed 1:
- Known Barrett's esophagus (reduces adenocarcinoma risk)
- Severe erosive esophagitis (Los Angeles grade C/D)
- Eosinophilic esophagitis responsive to PPI therapy
- Idiopathic pulmonary fibrosis
- High-risk patients requiring ongoing NSAID/aspirin therapy with history of ulcer complications
Bottom Line
PPIs are essential medications for multiple acid-related conditions extending well beyond simple heartburn. Their appropriate indications include peptic ulcers (treatment and prevention), GERD with its complications, H. pylori eradication, gastroprotection in high-risk NSAID/aspirin users, and several specialized conditions. 1, 2 However, they should only be used when a clear indication exists, as inappropriate use exposes patients to potential harms without benefit.